News
Atossa Therapeutics updates shareholders on clinical progress, ... In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCβ1, ...
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback